Clearside Biomedical, Inc. (CLSD)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Clearside Biomedical, Inc. (CLSD)
Company Performance

Current Price

as of Oct 16, 2024

$1.12

P/E Ratio

N/A

Market Cap

$83.72M

Description

Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Metrics

Overview

  • HQAlpharetta, GA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerCLSD
  • Price$1.12+0.90%

Trading Information

  • Market Cap$83.72M
  • Float84.64%
  • Average Daily Volume (1m)1,486,623
  • Average Daily Volume (3m)674,175
  • EPS-$0.50

Company

  • Revenue$7.52M
  • Rev Growth (1yr)-91.16%
  • Net Income-$7.59M
  • Gross Margin51.11%
  • EBITDA Margin-8,384.44%
  • EBITDA-$7.55M
  • EV$115.38M
  • EV/Revenue15.34
  • P/EN/A
  • P/S11.12
  • P/BN/A
Documents
SEC Filings
8-K (2024-10-09)
8-K (2024-08-12)
8-K (2024-07-24)
8-K (2024-06-20)
8-K (2024-05-09)
8-K (2024-04-16)
8-K (2024-03-12)
8-K (2024-02-08)
8-K (2024-02-01)
8-K (2023-12-28)
8-K (2023-11-13)
8-K (2023-11-03)
8-K (2023-09-29)
8-K (2023-08-14)
8-K (2023-06-22)
8-K (2023-05-12)
8-K (2023-05-11)
8-K (2023-04-18)
8-K (2023-03-09)
8-K (2023-02-21)
8-K (2023-02-06)
8-K (2023-02-02)
10-Q (2024-08-12)
10-Q (2024-05-10)
10-Q (2023-11-13)
10-Q (2023-08-14)
10-Q (2023-05-12)
10-K (2024-03-12)
10-K (2023-03-14)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Clearside Biomedical Q3 (2023-11-23T11:17:30Z)
Clearside Biomedical reports Q3 EPS ($0.15) vs FactSet ($0.16) [6 est, ($0.17)-(0.14)] ($0.95, 0.00) (2023-11-13T21:08:17Z)
Clearside Biomedical completes recruitment in ODYSSEY Phase 2B clinical trial of CLS-AX in wet AMD ($0.72, 0.00) (2023-11-01T11:16:39Z)
Clearside Biomedical announces clinical data presentations at AAO 2023 Annual Meeting ($1.14, 0.00) (2023-11-07T22:17:59Z)
BioCryst and Clearside Biomedical (CLSD) enter partnership to develop avoralstat for diabetic macular edema using Clearside's SCS Microinjector ($6.34, +0.70) (2023-11-03T16:09:16Z)
Earnings Calls
Earnings Report 2024Q1
Earnings Report 2023Q4
Earnings Report (2023-11-13)
Earnings Report (2023-08-14)
Factset
Factset Business Description